Is Materialise NV profitable in 2026?

Materialise's Medical segment ran a 32.0% adjusted EBITDA margin in FY2025, but Manufacturing lost -€4.2M EBITDA. Total FY2025 revenue was flat at €267.6M versus €266.8M in FY2024. Company held €134M cash at end-2025 with positive operating cash flow, per its Feb 19, 2026 results release.

Who owns Materialise NV?

Founder Wilfried Vancraen and his wife Hilde Ingelaere held combined beneficial ownership near 60% following the December 2020 merger of their holding vehicle Ailanthus NV into the company, per a SEC filing dated January 4, 2021. Materialise has traded publicly on Nasdaq as MTLS since its June 2014 IPO.

Could AI replace Materialise's software products?

Materialise shipped AI-enabled segmentation in Mimics 2025, but its Software segment still declined 6.8% to €40.9M in FY2025. Its Mimics/3-matic tools are regulated Class II/III medical device software requiring country-by-country approvals, a regulatory barrier AI alone cannot bypass, as of Feb 19, 2026 results.

Is Materialise laying off employees in 2026?

No layoffs were disclosed. Materialise's headcount stood at roughly 2,444 to 2,556 employees at year-end 2025, essentially flat versus 2024, per Revelio Labs (2026-06-29) and stockanalysis.com (2026-06-25) estimates.

Who is Materialise's biggest competitor?

Materialise competes with Stratasys, 3D Systems, EOS, and Nikon SLM Solutions in 3D-printing software and manufacturing, though it also co-formed the 'Leading Minds' consortium with these same firms plus HP, Renishaw, and TRUMPF at Formnext on November 18, 2024, to standardize industry workflows.

Is Materialise a safe company to join in 2026?

Materialise is a 36-year-old, cash-positive public company (€134M cash, end-2025) with a growing, regulated Medical segment (+15.4% YoY in FY2025). But it has been pruning weaker units, divesting RapidFit on March 31, 2026, and Eyewear on May 7, 2026, with expected Q2 2026 impairment charges.

Manufacturing companies · Belgium

Materialise NV

materialise.com ↗

Belgian firm selling 3D-printing software plus FDA-cleared medical planning tools and print services.

Defensible for now

Assessed 24 July 2026 · Evidence as of 24 July 2026

Real protection, with named pressure against it.

On the recordSince 24 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: Q2 2026 earnings call testing whether Manufacturing swings to positive EBITDA as guided

The call

Materialise stays cash-positive on regulated medical software while its manufacturing and general software segments keep losing ground to cheaper, faster-moving rivals.

Materialise makes software and services for 3D printing, with its Medical division (software for doctors and hospitals) generating half its sales and growing well with good profits. The other half, Manufacturing and Software tools, are shrinking or losing money, making them easier for competitors to take over or replace with newer tools. The company will stay afloat because Medical is solid and regulated, but real growth depends on whether the struggling Manufacturing business stops losing money by 2026 and whether the Software side can stabilize after adding AI features.

Why

AI pressure: AI-native medical image segmentation tools (e.g. Ansys/nTopology-style automation) challenging Mimics workflows. AI features shipped in Software segment but it still shrank 6.8%, suggesting rivals automate planning tasks faster than Materialise can. Could AI do the core job? Only partly.

Bigger players: Stratasys and 3D Systems in industrial manufacturing services. Bigger, better-funded rivals already compete for the same print-service contracts that pushed Materialise Manufacturing revenue down 13.2%. Could a giant copy it? Probably.

What protects it. Regulated FDA/CE clearances for Mimics and 3-matic lock hospitals into workflows that are costly and slow for rivals to replicate.

What would change this call

Materialise's Manufacturing segment reports positive adjusted EBITDA in FY2026 results. Would show the loss-making print-service unit stabilized instead of continuing to lose ground to rivals.
Software segment revenue decline widens beyond 10% year over year in a coming quarterly report. Would show AI feature launches failed to stop customers moving to competing design software.
Stratasys, 3D Systems, or GE Additive announce a hospital or medical-device contract win previously served by Materialise. Would show a shipped competitor is directly displacing Materialise's core Medical moat.

Key numbers

Medical revenue €134.2M, +15.4% YoY, 32% EBITDA margin (2026-02-19)
Manufacturing revenue fell 13.2% to €92.5M, EBITDA -€4.2M (2026-02-19)
Software revenue declined 6.8% to €40.9M despite AI features (2026-02-19)

Named risks

Manufacturing segment posted -€4.2M adjusted EBITDA in FY2025 and must swing positive in FY2026 as guided. Severity: high
Software segment revenue fell 6.8% in FY2025 despite shipped AI features, signaling weak monetization. Severity: medium
Company flagged continued macroeconomic and geopolitical uncertainty through FY2026 (as of May 8, 2026). Severity: medium
Impairment charges expected in Q2 2026 from RapidFit and Eyewear divestitures. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Stratasys	contesting	Co-formed Leading Minds workflow consortium with Materialise, Nov 18, 2024
3D Systems	contesting	Cited as direct medical/manufacturing peer alongside Materialise in industry reporting, 2026
Nikon SLM Solutions	contesting	Deepened build-processor software partnership with Materialise, Nov 18, 2025
EOS GmbH	contesting	Fellow Leading Minds consortium member competing in AM software/hardware, Nov 2024

Questions people ask

Is Materialise NV profitable in 2026?: Materialise's Medical segment ran a 32.0% adjusted EBITDA margin in FY2025, but Manufacturing lost -€4.2M EBITDA. Total FY2025 revenue was flat at €267.6M versus €266.8M in FY2024. Company held €134M cash at end-2025 with positive operating cash flow, per its Feb 19, 2026 results release.
Who owns Materialise NV?: Founder Wilfried Vancraen and his wife Hilde Ingelaere held combined beneficial ownership near 60% following the December 2020 merger of their holding vehicle Ailanthus NV into the company, per a SEC filing dated January 4, 2021. Materialise has traded publicly on Nasdaq as MTLS since its June 2014 IPO.
Could AI replace Materialise's software products?: Materialise shipped AI-enabled segmentation in Mimics 2025, but its Software segment still declined 6.8% to €40.9M in FY2025. Its Mimics/3-matic tools are regulated Class II/III medical device software requiring country-by-country approvals, a regulatory barrier AI alone cannot bypass, as of Feb 19, 2026 results.
Is Materialise laying off employees in 2026?: No layoffs were disclosed. Materialise's headcount stood at roughly 2,444 to 2,556 employees at year-end 2025, essentially flat versus 2024, per Revelio Labs (2026-06-29) and stockanalysis.com (2026-06-25) estimates.
Who is Materialise's biggest competitor?: Materialise competes with Stratasys, 3D Systems, EOS, and Nikon SLM Solutions in 3D-printing software and manufacturing, though it also co-formed the 'Leading Minds' consortium with these same firms plus HP, Renishaw, and TRUMPF at Formnext on November 18, 2024, to standardize industry workflows.
Is Materialise a safe company to join in 2026?: Materialise is a 36-year-old, cash-positive public company (€134M cash, end-2025) with a growing, regulated Medical segment (+15.4% YoY in FY2025). But it has been pruning weaker units, divesting RapidFit on March 31, 2026, and Eyewear on May 7, 2026, with expected Q2 2026 impairment charges.

Timeline

2026-07-20Buyback program had repurchased ~1.16M shares (2.0% outstanding) for ~€5.7M
2026-05-07Eyewear business transferred to newly formed independent company, minority stake retained
2026-05-06Q1 2026 results: revenue €66.3M, roughly flat YoY
2026-03-31RapidFit automotive jigs/fixtures business divested to its management team
2026-02-19FY2025 results: revenue €267.6M flat, Medical +15.4%, Manufacturing -13.2%, Software -6.8%
2026-01-26€30M ADS/share buyback program execution begins
2025-11-18Deepened co-development partnership with Nikon SLM Solutions on build-processor software
2025-10-30Announced Euronext Brussels listing and shareholder-approved €30M buyback program
2024-11-18Formed 'Leading Minds' consortium with Ansys, EOS, HP, Nikon SLM, Renishaw, Stratasys, TRUMPF
2021-01-04SEC filing shows founder/family ~60% combined ownership post Ailanthus merger

Revision history

24 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Boeing Vodafone Group LG Electronics